

Quarterly Report & Appendix 4C Q1 FY2026

Highlights:

- Major milestone achieved with the FDA lifting the clinical hold on the IND for NUZ-001 post-quarter end, clearing the path for entry into the HEALEY ALS Platform Trial
- Executed an exclusive global licensing agreement with Elanco Animal Health that secures access to a comprehensive package of non-clinical animal safety and GMP manufacturing data required for future regulatory approval
- The 12-month Open-Label Extension (OLE) study of NUZ-001 in patients with ALS/MND met its primary safety endpoint, showed preliminary signs of a long-lasting efficacy effect, and increased survival at the recommended Phase 2 dose compared to untreated matched controls from a natural history database
- Several patients continue to receive NUZ-001 under TGA Special Access Scheme
- Initiated GMP manufacture of NUZ-001 tablet registration batches at Catalent using full-scale commercial processes
- Awarded an Advance and Overseas Finding (AOF) from AusIndustry, enabling a cash rebate of at least 43.5% on eligible overseas R&D expenditure, including the HEALEY ALS Platform Trial, for the 2025–2027 financial years
- Successfully raised \$5.2m through a share placement with new and existing institutional investors with participation from the Board and management, in addition to \$1.5m received from a secured loan against the FY2025 R&D Tax Incentive rebate – total of \$5.6m expected Q2 FY2026
- Strengthened engagement with the ALS/MND community through local and international fundraising and awareness initiatives, reinforcing social responsibility alongside clinical and corporate priorities

Post Quarter-End Activities

- Common shares approved for trading on the OTCQB® Venture Market under ticker NUZTF, expected to enhance liquidity and visibility in the U.S. market
- Appointment of Integrous Communications to strengthen North American investor engagement ahead of HEALEY ALS Platform Trial commencement
- Australian patent granted covering NUZ-001 for the treatment of neurodegenerative diseases including ALS/MND and others such as Alzheimer’s disease, Huntington’s disease and Parkinson’s disease

29 October 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to provide its Appendix 4C and Quarterly Activities Report for the period ended 30 September 2025.

Operations during the quarter focused on strong execution of Neurizon’s stated regulatory and clinical development program for its lead drug candidate NUZ-001 for the treatment of Amyotrophic Lateral Sclerosis (ALS), the major form of motor neurone disease (MND).

In late July, the Company submitted a comprehensive Clinical Hold Complete Response (CHCR) to the U.S. Food and Drug Administration (FDA) to address the clinical hold on the Investigational New Drug (IND) application for NUZ-001. The CHCR detailed new data from two 28-day bridging pharmacokinetic (PK) studies in rats and dogs requested by the FDA to demonstrate adequate safety margins to the intended clinical dose.

In August, the FDA informed the Company that the review of the CHCR was delayed due to agency-wide resourcing constraints.

In early October, following the end of the quarter, the Company announced that the FDA had accepted the CHCR and lifted the clinical hold. With the NUZ-001 IND now successfully opened, Neurizon is well-positioned to accelerate NUZ-001 toward regulatory approval for ALS/MND through entry into the HEALEY ALS Platform Trial. This milestone also provides a strong regulatory foundation to unlock the value proposition of NUZ-001 as a platform molecule with potential applications across other neurodegenerative diseases.

This important regulatory milestone was accompanied by several other key derisking events during the quarter across various activities, including commercial, clinical, manufacturing, and financial, as follows:

Commercial:

Executed a global exclusive licensing agreement in early July with Elanco Animal Health, the world's fourth largest veterinary company, securing access to an extensive dataset of non-clinical animal safety and Good Manufacturing Practice (GMP) manufacturing data. These datasets support ongoing clinical development, regulatory submissions and future commercialisation of NUZ-001;

Clinical:

Released positive top-line data from a 12-month Open-Label Extension (OLE) study of NUZ-001 in patients with ALS/MND. The study successfully met its primary endpoint for long-term safety and showed initial signs of efficacy and increased survival at the recommended Phase 2 dose;

Manufacturing:

Successfully commenced GMP manufacture of NUZ-001 tablet registration batches at Catalent, using full-scale commercial processes;

Financial:

In September, Neurizon was awarded an Advance and Overseas Finding (AOF) from AusIndustry, enabling the Company to claim a cash rebate of at least 43.5% for eligible overseas R&D expenditure, including the HEALEY ALS Platform Trial, for the 2025–2027 financial years. The Company also completed a strategic capital raising of \$5.2m, supported by new and existing institutional investors, management and the Board of Directors.

Throughout the quarter, Neurizon continued its strong engagement with the ALS/MND community and patient advocacy groups, maintaining its commitment to social responsibility through fundraising campaigns and awareness events highlighting the impact of ALS/MND. These initiatives remain a key priority alongside the Company's clinical and corporate programs.

Managing Director and Chief Executive Officer, Dr Michael Thurn commented: "This quarter has seen significant advances for Neurizon, highlighted by the FDA lifting the clinical hold on NUZ-001, the signing of an exclusive worldwide licensing agreement with Elanco Animal Health, and securing substantial future non-dilutive funding through AusIndustry for eligible overseas R&D expenditure, including the HEALEY ALS Platform Trial, for the next three financial years. These milestones represent a crucial step towards accelerating NUZ-001 as a potential new treatment for ALS.

At the same time, we strengthened our balance sheet through a successful \$5.2m capital raising, a \$1.5m loan from Radium Capital, and expanded investor access with our U.S. OTCQB quotation, enhancing liquidity and visibility as we progress toward a critical value inflection point with the HEALEY ALS Platform trial.

Neurizon is now well-positioned to deliver on our mission of bringing life-changing therapies to people living with ALS."

Regulatory Engagement and Clinical Progress

During the quarter, Neurizon advanced its regulatory engagement with the FDA to address the clinical hold on NUZ-001. The Company received positive written guidance in July confirming its proposed strategy was appropriate and successfully completed the requested bridging PK studies ahead of schedule.

The CHCR incorporating these data was submitted later in the month, and the FDA review was finalised post-quarter, culminating with the clinical hold being lifted in October. This major milestone enables Neurizon to proceed with entry into the HEALEY ALS Platform Trial during the current quarter.

Neurizon reported topline results from the OLE study. The OLE study was an open-label, safety, tolerability, and preliminary efficacy study of NUZ-001 in 10 patients with ALS/MND who completed the Phase 1 MEND Study, at the recommended Phase 2 dose of 10 mg/kg administered orally daily for 12-months. The study met its primary endpoint, confirming long-term daily dosing with NUZ-001 at the recommended Phase 2 dose was safe and well-tolerated. No new safety concerns were identified, with no treatment-related SAEs or deaths.

Encouraging preliminary efficacy outcomes further support the advancement of NUZ-001. Compared with matched historical controls (PRO-ACT database), treatment with NUZ-001 was associated with a significant survival benefit (HR=0.233, p=0.0013), corresponding to an estimated 16-month median survival extension, a 76.7% reduction in risk of death. Functional (ALSFRS-R 31% slower decline) and respiratory (SVC 43% slower decline) outcomes were directionally consistent with the survival effect (nominal p=0.145 and 0.078, respectively). Biomarker trends, including stable plasma neurofilament light chain levels and a 17% reduction in urinary p75ECD, reinforced the durability of clinical benefit observed.

In partnership with Key Opinion Leaders (KOLs) and clinical experts, Neurizon continued developing a comprehensive multi-omics biomarker strategy for the upcoming HEALEY ALS Platform Trial, focusing on neurofilament light chain (NfL) and other disease-relevant biomarkers.

Together, these results and plans strengthen the clinical and regulatory foundation for NUZ-001 and underpin Neurizon's entry into the HEALEY ALS Platform Trial in Q2 FY2026.

Commercialisation Initiatives

In early July, Neurizon announced that it had entered into an exclusive global licensing agreement with Elanco Animal Health. This strategic agreement provides Neurizon with access to Elanco's extensive package of non-clinical animal safety and manufacturing data, as well as key intellectual property supporting the development of NUZ-001. In addition, it includes the key terms for a manufacturing and supply agreement that will secure a long-term, scalable source of GMP-compliant NUZ-001 expected to be finalised this current quarter. This represents a significant milestone for the Company, securing rights that not only strengthen the regulatory submission package but reduce the timeline for regulatory approval.

In parallel with this licensing progress, Neurizon reached a major manufacturing milestone with the commencement of the manufacture of GMP registration batches of NUZ-001 at Catalent, a leading global contract development and manufacturing organisation. Manufacturing commenced using full-scale commercial processes and equipment in compliance with FDA and ICH standards, ensuring alignment with the rigorous requirements of future regulatory filings.

The registration batches are being produced at a one-tenth commercial scale and will be used to generate essential data for the Company's planned New Drug Application (NDA). This includes stability and shelf-life studies, validation of commercial-scale processes, and the compilation of the Chemistry, Manufacturing, and Controls (CMC) module of the NDA.

Capital Markets and Funding Activity

In July, Neurizon executed a loan agreement for \$1.5m secured against its Australian Federal Government's R&D Tax Incentive scheme rebate for the 2025 financial year (2025 R&D Tax Rebate). This loan provided a flexible, non-

dilutive funding on top of Neurizon's existing cash balance. This was complemented in September by the award of an Advance & Overseas Finding from AusIndustry. This finding, which is binding on AusIndustry and the Commissioner of Taxation for FY2025–FY2027, confirms that planned overseas R&D activity—spanning pre-clinical, manufacturing, regulatory and clinical programs, including the HEALEY ALS Platform Trial—is eligible under the R&D Tax Incentive cash rebate rate of at least 43.5%. For FY2025, Neurizon expects to receive approximately \$5.6 million in Q2 FY2026, of which \$1.5m has been advanced via Radium Capital. As a result, there is an anticipated net receipt of approximately \$4.1m (before fees and interest).

In addition, Neurizon raised \$5.0m through a placement of fully paid ordinary shares at \$0.12 per share. The placement attracted strong demand and was well supported by both new and existing investors with significant support from institutional investors. In addition, the Board and management demonstrated their alignment with shareholders by committing a further \$0.2m in subscriptions, with \$130k of this subject to shareholder approval. This outcome underscores confidence in the Company's strategy and the clinical potential of NUZ-001.

This funding strengthens Neurizon's balance sheet at a critical stage of its development. Proceeds will be directed towards advancing the Company's participation in the HEALEY ALS Platform Trial, as well as supporting pre-clinical programs, GMP manufacturing activities, regulatory submissions, and general working capital requirements. This financing ensures the Company is well-positioned to maintain operational momentum while advancing both its lead program and broader pipeline opportunities.

Community and Industry Engagement Initiatives

During the quarter, Neurizon remained highly active across key scientific, investor, and patient-focused events, reinforcing its commitment to collaboration, transparency, and patient-centred innovation.

The Company participated in a series of global scientific conferences and leading investor forums and roadshows. These events provided opportunities to showcase Neurizon's clinical and scientific progress, expand engagement with potential global partners, and strengthen relationships across the biotech and investor communities.

Some of these events include:

- ALS Nexus Conference (August 11-14, Texas, U.S.)
- Shareholder Update Webinar (August 26)
- PACTALS (September 7-9, Melbourne, AU)
- FightMND's Global MND Research Roundtable (September 10-12, Melbourne, AU)
- Australian Investor Roadshow (September 15-17)
- HealthInvest (September 24, Sydney, AU)

Post-quarter, Neurizon's leadership, clinical, and research teams participated in the 2025 Annual NEALS Meeting held from 7–10 October in Florida, U.S., one of the world's foremost gatherings in ALS/MND research. At the meeting, Neurizon presented NUZ-001 to HEALEY clinical sites and contributed to the scientific dialogue through a poster presentation highlighting the latest preclinical developments. This engagement reflects Neurizon's continued collaboration with global thought leaders and clinical partners dedicated to advancing ALS/MND research and treatment.

The Company maintained a strong presence across key international partnering and investment forums, including BioJapan (October 8–10, Yokohama), the Ignite Investment Summit (October 15–16, Hong Kong), the 14th Annual Australian Microcap Investment Conference (October 21, Melbourne), and AusBiotech 2025 (October 21–24, Melbourne). In addition, Neurizon's management team conducted a focused investor roadshow across Hong Kong and Singapore, strengthening relationships with institutional investors and potential partners in the Asia-Pacific region.

Neurizon also participated in the ALS Association's Walk to Defeat ALS event in Boston (October 26), walking alongside patients, families, clinicians, and advocates to raise awareness and funding for ALS/MND research. This

initiative reflects Neurizon's patient-first mission, standing with the ALS/MND community and recognising that every step taken brings us closer to effective treatments and a cure.

Ongoing engagement with patient associations and advocacy groups continued to play a central role in Neurizon's communications and development activities. The Company works closely with organisations across Australia, the USA, and Europe to ensure its programs reflect patient priorities and to strengthen global collaboration around access, education, and awareness for ALS/MND and other neurodegenerative diseases.

Looking ahead, Neurizon remains focused on expanding its global presence, advancing awareness, forging strategic partnerships, and engaging with the broader scientific and patient communities across a series of major industry and research events in the months ahead.

- ALS Association Roundtable (November 13, DC, U.S.)
- The Annual Society of Neuroscience Conference (November 15-19, CA, U.S.)
- 36th International Symposium on ALS/MND (December 5-7, CA, U.S.)
- JP Morgan Healthcare Conference (January 12-15, CA, U.S.)

Through these combined efforts, Neurizon continues to build recognition as a science-led, patient-driven, and globally connected company, committed to advancing meaningful progress for people living with ALS/MND and related neurodegenerative diseases.

Additional Events Subsequent to End of Quarter

Post quarter-end, Neurizon achieved a major regulatory milestone with the U.S. FDA lifting the clinical hold on NUZ-001. This enables the Company to proceed with its planned entry into the HEALEY ALS Platform Trial later this year. The IND application supporting this decision was underpinned by a robust package of preclinical safety studies, long-term clinical safety data, and comprehensive manufacturing information secured through the strategic licensing agreement with Elanco Animal Health.

Neurizon also broadened its capital markets presence with the approval of its common shares for trading on the U.S. OTCQB® Venture Market under the ticker NUZTF. The OTCQB quotation enhances trading liquidity, increases visibility with USA investors, and provides a platform for deeper engagement across a larger international shareholder base. To further support this expansion, the Company appointed Integrous Communications, a leading USA investor relations firm with deep life sciences expertise, to strengthen its North American investor relations program. These initiatives collectively provide Neurizon with greater reach and visibility ahead of the Company's next stage of clinical and corporate growth.

Post quarter-end, Neurizon also further strengthened its global IP portfolio and commercialisation opportunities through the grant of its Australian patent covering NUZ-001 for treating neurodegenerative diseases, including ALS/MND, Alzheimer's, Huntington's, and Parkinson's. This complements the expedited U.S. patent issued earlier this year and provides protection until May 2041 across major markets.

Near-term Outlook and Value Catalysts

Development	Timing
Submit NUZ-001 protocol amendment to U.S. FDA for HEALEY ALS Platform Trial	Q2 FY2026
Completion of second and third GMP registration batches of NUZ-001	Q2 FY2026
FDA's confirmation of entry into HEALEY ALS Platform Trial	Q2 FY2026
Fast Track Designation of NUZ-001 for ALS/MND	Q2 FY2026
Site activation for HEALEY ALS Platform Trial	Q3 FY2026
Commencement of patient recruitment for HEALEY ALS Platform Trial	Q3 FY2026
First patient enrolled for HEALEY ALS Platform Trial	Q3 FY2026
Preclinical work to broaden pipeline to other neurodegenerative diseases	Ongoing
Partnership expansion opportunities with patient associations	Ongoing
Engagement with potential strategic partners	Ongoing

Cash Flow Summary

During the quarter, Neurizon continued to fund the advancement of its clinical development program for NUZ-001. Neurizon had net cash outflows from operating activities of \$3.7m during the quarter and held \$6.6m in cash and cash equivalents as at 30 September 2025.

Cash outflow from operating activities during the quarter represented a further reduction on prior quarter spend of approximately 17.5%, with a continued prudent approach to spend in advance of planned entry into the HEALEY ALS Platform Trial, while still progressing Neurizon's strategic preclinical work program and closing out the OLE clinical study. Consistent with prior quarters, Neurizon's cash outflow for the quarter focused predominantly on research and development activities.

As outlined above, following receipt of an AOF, Neurizon now expects to receive an R&D Tax Rebate of approximately \$5.6 million in Q2 FY2026, of which \$1.5 million has been advanced via Radium Capital. As a result, Neurizon anticipates a net receipt of approximately \$4.1 million (before fees and interest) in Q2 FY2026.

Payments to related parties and their associates during the quarter, which are outlined in Section 6 of the accompanying Appendix 4C to this quarterly activity report, were \$163k. These payments included non-executive director fees as well as salary (including superannuation) for the CEO and Managing Director.

A copy of the Appendix 4C – Quarterly Cash Flow Report for the quarter is attached.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics

Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations

Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations

Matthew Selinger
Integrus Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.

This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited.
OTCQB® Venture Market is a registered trademark of OTC Markets Group Inc.

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Neurizon Therapeutics Limited

ABN

35 094 006 023

Quarter ended ("current quarter")

30 September 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(2,301)	(2,301)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(91)	(91)
(d) leased assets	-	-
(e) staff costs	(443)	(443)
(f) administration and corporate costs	(847)	(847)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	14	14
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(3,668)	(3,668)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(3)	(3)
(d) term deposits with maturities longer than 3 months at acquisition	-	-
(e) intellectual property	(154)	(154)

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) term deposits with maturities longer than 3 months at acquisition	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(157)	(157)
3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	5,070	5,070
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	(327)	(327)
3.5 Proceeds from borrowings	1,494	1,494
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other	-	-
3.10 Net cash from / (used in) financing activities	6,237	6,237

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,161	4,161
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,668)	(3,668)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(157)	(157)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	6,237	6,237
4.5	Effect of movement in exchange rates on cash held	(1)	(1)
4.6	Cash and cash equivalents at end of period	6,572	6,572

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	6,572	4,161
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	6,572	4,161

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	163
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	1,494	1,494
7.2 Credit standby arrangements	-	-
7.3 Other*	-	-
7.4 Total financing facilities	1,494	1,494
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
Lender: Radium Capital Interest rate: 17% per annum Maturity date: 31 December 2025 Secured against R&D Tax Australian Government R&D Tax Rebate		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,668)
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,572
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	6,572
8.5	Estimated quarters of funding available based on cash and cash equivalents under AASB 107 (item 8.4 divided by item 8.1)	1.792
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	The cash outflow from operating activities for the September quarter was lower than in the prior two quarters. In advance of commencement of the HEALEY ALS Platform Trial, the spend covered other key elements of Neurizon Therapeutics strategy, including ongoing clinical progress (Phase 1 OLE finalisation, FDA complete response, GMP manufacturing, HEALEY ALS Platform Trial readiness), continued execution of the pre-clinical strategy, ongoing regulatory and commercial planning and stakeholder engagement. Spend in subsequent quarters is expected to include costs associated with commencement and execution of the HEALEY ALS Platform Trial.	

8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
	<p>Neurizon expects to receive approximately \$5.6 million in Q4 CY2025 through the Australian Government R&D Tax Rebate. As previously announced, \$1.5 million has been advanced via a loan from Radium Capital, a specialist R&D lender. Accordingly, Neurizon expects to net an additional \$4.1 million (approximately), before fees and interest, following repayment of the loan.</p> <p>Neurizon remains focused on prudent capital management and continues to assess strategic commercial and capital management options to support business operations and long-term value creation. Management remains confident in its ability to secure appropriate funding solutions in a timely manner, as required.</p>
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	<p>The Company expects to be able to continue its operations and meet its business objectives on an ongoing basis. Achieved by prudently utilising available cash and executing an appropriate commercial and / or capital solution as and when required.</p> <p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 October 2025

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.